Overview

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

Status:
Terminated

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

A Phase 2a study to evaluate the effects of an investigational compound administered at 200 mg, twice daily (BID), for 6 weeks, with canagliflozin, in adult subjects with Type 2 Diabetes Mellitus (T2DM).

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Canagliflozin